A Phase I Trial of Combined PD-1 Inhibition (Pembrolizumab) and CCR5 Inhibition (Maraviroc) for the Treatment of Refractory Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 17 Dec 2018
Price : $35 *
At a glance
- Drugs Maraviroc (Primary) ; Pembrolizumab (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Acronyms PICCASSO
- 13 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 09 Apr 2018 Status changed from not yet recruiting to recruiting.
- 11 Sep 2017 New trial record